Bristol-Myers Squibb And Medarex To Refile Oncology Agreement With FTC
This article was originally published in The Pink Sheet Daily
Executive Summary
The Federal Trade Commission requests additional information related to Bristol's $192 mil. development agreement for Medarex' metastatic melanoma agent. The extended review period is expected to expire in January.